Binding of Heparin/Heparan Sulfate to Fibroblast Growth Factor Receptor 4*

Britt-Marie LooDagger §, Johan Kreuger§, Markku Jalkanen, Ulf Lindahl§, and Markku SalmivirtaDagger §||

From the Dagger  Turku Centre for Biotechnology, University of Turku and Åbo Akademi University, FIN-20521 Turku, Finland, the § Department of Medical Biochemistry and Microbiology, Uppsala University, S-75123 Uppsala, Sweden, and  BioTie Therapies Corp., FIN-20520 Turku, Finland

Received for publication, December 13, 2000, and in revised form, January 22, 2001


    ABSTRACT
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

Fibroblast growth factors (FGFs) are heparin-binding polypeptides that affect the growth, differentiation, and migration of many cell types. FGFs signal by binding and activating cell surface FGF receptors (FGFRs) with intracellular tyrosine kinase domains. The signaling involves ligand-induced receptor dimerization and autophosphorylation, followed by downstream transfer of the signal. The sulfated glycosaminoglycans heparin and heparan sulfate bind both FGFs and FGFRs and enhance FGF signaling by mediating complex formation between the growth factor and receptor components. Whereas the heparin/heparan sulfate structures involved in FGF binding have been studied in some detail, little information has been available on saccharide structures mediating binding to FGFRs. We have performed structural characterization of heparin/heparan sulfate oligosaccharides with affinity toward FGFR4. The binding of heparin oligosaccharides to FGFR4 increased with increasing fragment length, the minimal binding domains being contained within eight monosaccharide units. The FGFR4-binding saccharide domains contained both 2-O-sulfated iduronic acid and 6-O-sulfated N-sulfoglucosamine residues, as shown by experiments with selectively desulfated heparin, compositional disaccharide analysis, and a novel exoenzyme-based sequence analysis of heparan sulfate oligosaccharides. Structurally distinct heparan sulfate octasaccharides differed in binding to FGFR4. Sequence analysis suggested that the affinity of the interaction depended on the number of 6-O-sulfate groups but not on their precise location.


    INTRODUCTION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

The fibroblast growth factors (FGFs)1 belong to a family of about 20 related polypeptides. They display biological activity toward cells of mesenchymal, neuronal, and epithelial origin and are involved in processes such as cell growth, organ development, and angiogenesis (1). The biological effects of FGFs are exerted through interactions with FGF receptors (FGFRs). The receptor family consists of four known members, FGFR1-4, with many isoforms (2). Upon ligand binding the receptor is thought to be activated through dimerization and phosphorylation by the intracellular tyrosine kinase domains (3). Heparan sulfate proteoglycans (HSPGs), abundant components of cell surfaces and the extracellular matrix, appear central to signaling through FGF·FGFR complexes (for reviews, see Refs. 4-6). Cells lacking endogenous HSPGs respond poorly to FGF, whereas the response can be readily restored by addition of exogenous heparin (7, 8). Accumulated evidence points to formation of biologically active complexes involving FGF, FGFR, and HSPGs, in which heparan sulfate interacts with both the FGF and FGFR components of the complex (9-11). A direct interaction between HSPGs and FGFRs appears critical for FGFR activation (12). A heparin-binding domain identified in the second Ig-loop of the four FGFRs comprises sequence of about 20 amino acids toward the NH2 terminus of the loop (12). Different splice variants of the receptors differ in affinity for heparin, such that the interaction may vary with the structure of the extracellular receptor domain (13).

Heparin/HS chains are initially synthesized as polymers of alternating glucuronic acid (GlcA) and N-acetylglucosamine (GlcNAc) units (for reviews, see Refs. 14-16). In HS biosynthesis, the polymer is first modified by partial N-deacetylation/N-sulfation of GlcNAc residues. The further modification reactions, C5-epimerization of GlcA to iduronic acid (IdoA) units and O-sulfation at various positions (C2 of IdoA and GlcA, C3 and C6 of GlcN units), all occur in the vicinity of previously incorporated N-sulfate groups. Heparin, a highly specialized product of mast cells, is more extensively modified than HS and the modifications are more evenly distributed along the polymer (14).

The heparin/HS structures required for FGFR binding are poorly defined. However, both IdoA(2-OSO3) and GlcNSO3(6-OSO3) residues appear to be required for the FGF2 induced activation of FGFR1, whereas 2-O-sulfate groups alone are sufficient to mediate binding to FGF2 (11, 17, 18). While these findings suggest a role for 6-O-sulfated GlcNSO3 residues in the interactions with FGFR1, it would seem likely that different FGFRs may bind structurally distinct HS species. Neuroepithelial HSPG thus preferentially bound FGFR1 at the cell surface although FGFR3 was also present (19). The importance of polysaccharide-FGFR interaction was underpinned by the finding that heparin could alone induce phosphorylation of FGFR4 in the absence of an FGF ligand (20).

In the present paper we describe FGF-independent binding of heparin and HS to the extracellular domain of FGFR4. We show that the interaction is mediated by N-sulfated octasaccharides that contain both IdoA(2-OSO3) and GlcNSO3(6-OSO3) residues, and provide sequence data for FGFR4-binding HS domains.

    EXPERIMENTAL PROCEDURES
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

Materials-- All studies were performed using the soluble extracellular domain of FGFR4. The expression and purification of recombinant human FGFR4, containing the three extracellular Ig domains (Ser25-Arg366), were as described earlier (21). Briefly, the His-tagged protein was expressed in Sf9 insect cells and purified directly from the culture medium by nickel and heparin affinity chromatography. Heparin from pig intestinal mucosa (stage 14, Inolex Pharmaceutical Division, Park Forest South, IL), was purified as previously described (22). It was used either unlabeled or radiolabeled by 3H-acetylation of free amino groups (specific activity 75,300 dpm/nmol) as described (23). The selectively desulfated heparin preparations and oligosaccharides of bovine lung heparin (24, 25) were a kind gift from Dr. Dorothe Spillmann (Uppsala University, Uppsala, Sweden). Heparan sulfate preparations from bovine aorta, kidney, lung, and intestine were generously provided by Dr. Keiichi Yoshida (Seikagaku Corp., Tokyo, Japan). N-Sulfated HS oligosaccharides were prepared from bovine intestinal mucosa heparan sulfate (a gift from Kabi AB, Stockholm, Sweden) and 3H-labeled as described previously (26). Briefly, HS was N-deacetylated by hydrazinolysis followed by treatment with nitrous acid at pH 3.9, resulting in cleavage at the N-unsubstituted GlcN residues. The resistent N-sulfated oligosaccharides were recovered, reduced with NaB3H4 (28 Ci/mmol, Amersham Pharmacia Biotech, Uppsala, Sweden), and separated by gel chromatography. The column materials, Sephadex G-15 and CH-Sepharose-4B, were obtained from Amersham Pharmacia Biotech, as were the PD-10 desalting and Superdex 30 columns. The Partisil-10 HPLC column (4.6 × 250 mm) was from Whatman Inc., Clifton, NJ, and the Propac PA1 HPLC column was from Dionex, Surrey, United Kingdom.

Binding Studies-- In the filter-trapping assay (27), radiolabeled glycosaminoglycans were incubated with FGFR4 in 8.1 mM Na2HPO4, 1.5 mM KH2PO4, 2.7 mM KCl, and 140 mM NaCl, pH 7.4 (PBS), containing 0.1 mg/ml bovine serum albumin, in a total volume of 200 µl for 2 h at room temperature. The mixtures were rapidly passed through nitrocellulose filters (Sartorius, diameter 25 mm, pore size 0.45 µm) using a vacuum suction apparatus, followed by washing with PBS. Proteins and protein bound saccharides remain on the filter whereas unbound saccharides pass through. The bound saccharides were released by 2 M NaCl and quantified by a beta -scintillation counter.

Binding studies were also performed using a CH Sepharose-4B column, with immobilized FGFR4, that was prepared according to the instructions of the manufacturer. For preparation of 1 ml of the affinity matrix, ~0.5 mg of FGFR4 was used. Heparin (0.5 mg) was included in the immobilization reaction to protect the heparin-binding site on FGFR4. To avoid immobilization of heparin to the matrix, the heparin preparation used had been treated with HNO2 at pH 3.9 (28) to destroy any N-unsubstituted GlcN residues, followed by recovery of the high molecular weight fraction by gel chromatography on Superdex 30. Samples of 3H-labeled heparin/HS were applied to the column in PBS, with or without CaCl2 supplementation, followed by washing with PBS and elution of the bound material with a linear gradient of NaCl (0.14-1.0 M) in PBS at a flow rate of 0.5 ml/min. Fractions of 1 ml were collected and measured for radioactivity. The NaCl gradient was monitored by measuring the conductivity of every third fraction. A control column was prepared without immobilized FGFR4. This column did not bind any of the tested glycosaminoglycans (data not shown). To study the interaction of the antithrombin (AT) binding heparin domain with FGFR4, 3H-labeled heparin decasaccharides were subjected to affinity chromatography on antithrombin-Sepharose as described (29). Bound decasaccharides were eluted with a step gradient of NaCl (0.14, 0.5, and 2.0 M NaCl in 50 mM Tris-HCl, pH 7.4). The high affinity (~2% of total saccharide) and non-binding fractions recovered in the 2.0 and 0.14 M NaCl eluates, respectively, were tested for FGFR4 binding by affinity chromatography.

Surface plasmon resonance analysis on a BiacoreX instrument (BiaCore AB, Uppsala, Sweden) was a third means of studying saccharide:FGFR4 binding. Heparin (0.5-1 mg) was biotinylated by incubation in 0.1 M MES buffer (pH 5.5 with 50 mM biotin hydrazide (Calbiochem, San Diego, CA) and 10 mM N-ethyl-N'(dimethylaminopropyl)carbodiimide (Pierce Chemical Corp., Rockford, IL) for 5-6 h at room temperature. Biotinylated heparin was separated from excess reagent on a PD-10 column and immobilized to streptavidin-coated sensor chips (BiaCore AB). FGFR4 was incubated with saccharides for at least 10 min prior to injection over the heparin-coated surface. The running buffer used was PBS supplemented with 0.005% Tween 20. The concentrations of the interactants and flow rates were as indicated in the figure legends. A streptavidin surface without immobilized heparin was used as a control. The response from this surface was subtracted from the response of the heparin surface.

Compositional Analysis of Heparan Sulfate-- N-Sulfated oligosaccharides from bovine intestinal HS were fractionated by binding to the FGFR4 affinity matrix. To deplete the unbound pool (~80% of the total saccharide) of any remaining FGFR4 binding components, it was rechromatographed twice on the FGFR4 column (<4% of the material was bound to the matrix upon the second rechromatography step). The disaccharide composition of HS samples was determined as described (30, 31). Briefly, saccharides were treated with nitrous acid (HNO2) at pH 1.5, leading to deaminative cleavage of the saccharide chain at GlcNSO3 units (28). The resultant terminal anhydromannose units were radiolabeled by reduction with NaB3H4 (0.25-0.5 mCi/reaction) yielding 3H-labeled 2,5-anhydromannitol ([3H]aManR) residues. The labeled disaccharides were recovered by gel chromatography and further separated by anion-exchange HPLC on a Partisil-10 SAX column eluted with a step gradient of KH2PO4. The disaccharide peaks were identified by comparing their elution positions to those of standard heparin disaccharides. The proportions of non-O-sulfated disaccharides were determined by high voltage paper electrophoresis of the total labeled disaccharides in 0.83 M pyridine, 0.5 M acetic acid buffer, pH 5.3 (32).

Sequence Analysis-- FGFR4 binding HS oligosaccharides, containing a reducing terminal [3H]aManR residue, were prepared for sequence analysis by anion-exchange HPLC on a Propac PA1 column in H2O, pH 3 (adjusted with HCl). The bound oligosaccharides were eluted with a linear gradient of NaCl (up to 1.5 M). The fractions containing the octasaccharides of interest were pooled, desalted, dried in a centrifugal evaporator, and sequenced through a combination of chemical and enzymatic degradation procedures as described (33). Samples were first subjected to partial HNO2 (pHNO2) cleavage (34) by treatment with 2 mM NaNO2 in 20 mM HCl on ice. After incubation for various periods of time (30, 60, 90, 120, and 180 min), aliquots were removed and the reaction was stopped by addition of 200 mM sodium acetate, pH 6. The aliquots, containing the cleavage products from the different time points, were combined and subjected to enzyme digestion. The exoenzymes used for sequence analysis were iduronate-2-sulfatase (IdoA2Sase), alpha -L-iduronidase (IdoAase), and glucosamine-6-sulfatase (GlcN6Sase) (Oxford GlycoSciences, Abingdon, U.K.). The enzymes are recombinant human (IdoA2Sase and IdoAase) or caprine (GlcN6Sase) proteins produced in Chinese hamster ovary K1 cells. IdoA2Sase removes ester sulfates at C2 of nonreducing terminal IdoA(2-OSO3) residues of heparin/heparan sulfate whereas IdoAase cleaves the alpha 1-4 linkage between IdoA and GlcNR in heparin/heparan sulfate (R is -COCH3, -SO<UP><SUB>3</SUB><SUP>−</SUP></UP>, or -H3). GlcN6Sase cleaves ester sulfates at C6 of nonreducing GlcNR residues. The substrate specificities of the enzymes were confirmed using known heparin structures as substrates. IdoA2Sase and IdoAase were shown to be active on all potential substrates including heparin disaccharide deamination products. Notably, 6-O-sulfated aManR is not a substrate for GlcN6Sase.2 The amounts of enzyme used were 1 milliunit/reaction of IdoA2Sase/IdoAase, and 0.2 milliunits/reaction of GlcN6Sase. The samples were incubated with a single enzyme or combinations of the enzymes in a total volume of 25 µl, in the incubation buffer provided with the enzymes (50 mM sodium acetate, pH 5.0, and 0.1 mg/ml bovine serum albumin) at 37 °C for 13-15 h. In digestions involving several enzymes, the enzymes were added at 2-h intervals, in the order of action. The enzyme-treated saccharides were analyzed by Propac ion-exchange chromatography as described above. Sequence information was obtained by detecting shifts in the elution positions of the enzyme-treated subfragments (33, 34).

    RESULTS
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

Binding of Heparin to the Extracellular Domain of FGFR4-- To assess the binding of the recombinant extracellular domain of FGFR4 to heparin, increasing amounts of [3H]heparin were incubated with FGFR4 at physiological ionic strength. The protein-polysaccharide complexes formed were trapped on nitrocellulose filters and the bound saccharide was quantified by scintillation counting (27). The results indicated that heparin bound FGFR4 in a dose-dependent and saturable manner (Fig. 1A), whereas the binding was completely abolished by addition of excess cold heparin (data not shown). A KD value of 0.3-0.4 µM was determined for the FGFR-heparin interaction (assuming an average molecular weight of 10 kDa for heparin) by fitting a hyperbolic function using nonlinear regression analysis to the data visualized by a Scatchard plot (inset, Fig. 1A). The interaction was also studied by affinity chromatography of [3H]heparin on immobilized FGFR4, as well as by surface plasmon resonance (BiaCore) measurements of soluble FGFR4 binding to immobilized heparin. In affinity chromatography, [3H]heparin was found to require 0.25-0.50 M NaCl for elution from the FGFR4 column (Fig. 1B). Surface plasmon resonance analysis showed saturable binding of FGFR4 to the heparin-coated surface whereas little or no binding was seen to a control surface without heparin (data not shown). Together, these data indicate that the FGFR4 ectodomain is capable of binding heparin in a FGF-ligand independent fashion, in agreement with previous results (20, 21, 35).


View larger version (20K):
[in this window]
[in a new window]
 
Fig. 1.   Interaction of heparin with the extracellular domain of FGFR4. A, [3H]heparin was incubated with FGFR4 (20 µg/ml) in PBS for 2 h. The formed FGFR4-heparin complexes were recovered on nitrocellulose filters and the filter bound radioactivity was quantified by liquid scintillation counting (see "Experimental Procedures"). Inset shows a Scatchard plot based on the binding data. B, affinity chromatography of [3H]heparin on immobilized FGFR4. Samples of [3H]heparin (10,000 dpm) were applied to the FGFR4 column in calcium-free PBS (- - - -) or PBS containing 1.3 mM CaCl2 (---). The bound material was eluted with a linear gradient of NaCl. Fractions of 1 ml were collected and analyzed for radioactivity.

An important role for divalent cations such as Ca2+ in the binding of heparin to FGFR1, another member of the FGFR family, were proposed by McKeehan and co-workers (36, 37). To examine whether calcium ions affect the heparin-FGFR4 interaction, we tested the binding of [3H]heparin to the FGFR4 affinity matrix in the presence of 1.3 mM Ca2+, which corresponds to the physiological Ca2+ concentration of extracellular fluids. Under these conditions, the peak elution of [3H]heparin occurred at ~0.40 M NaCl, as compared with a peak elution position corresponding to ~0.35 M NaCl in the absence of Ca2+ ions (Fig. 1B). These results suggest that Ca2+ ions may slightly enhance, but are not required for, the heparin-FGFR4 interaction.

Structural Requirements for Binding of Heparin to FGFR4-- To identify the minimal size of the FGFR4 binding heparin domain, even numbered, 3H-end-labeled heparin oligosaccharides were incubated with FGFR4 in solution, after which the binding was assessed by the filter-trapping method (see "Experimental Procedures"). Octasaccharides were the shortest oligosaccharides with appreciable FGFR4 binding capacity (Fig. 2A). The binding of decasaccharides and longer fragments to FGFR4 increased gradually with increasing fragment length, but without any striking differences in binding between the consecutive fragments of the series. Surface plasmon resonance was also used to define the minimal FGFR4-binding heparin domain by assessing the ability of heparin oligosaccharides to inhibit binding of FGFR4 to biotinylated full-length heparin, immobilized on the chip surface (Fig. 2B). Octasaccharides were the smallest fragments with substantial inhibitory capacity, whereas decasaccharides and longer fragments had still higher inhibitory effect. Taken together, the above data implicate a minimal FGFR4-binding site within a sequence encompassing eight monosaccharide units.


View larger version (19K):
[in this window]
[in a new window]
 
Fig. 2.   Binding of heparin oligosaccharides to FGFR4. A, the binding of even-numbered, 3H-labeled heparin oligosaccharides (20,000 dpm) to FGFR4 (15 µg/ml) was studied by the filter trapping assay (see legend to Fig. 1 and "Experimental Procedures"). B, surface plasmon resonance analysis of the capacity of heparin oligosaccharides to inhibit the binding of soluble FGFR4 to immobilized heparin. Heparin oligosaccharides (16 µg/ml) were incubated with FGFR4 (0.4 ng/ml) and injected, at a flow rate of 30 µl/min, over biotinylated heparin immobilized onto the streptavidin-coated sensor chip surface. The response representing the binding of FGFR4 to heparin in the absence of competitors was set to 100%. H, full-length heparin.

We next studied the importance of the N-, 2-O-, and 6-O-sulfate groups of heparin in FGFR4 binding, by testing the ability of selectively desulfated heparin preparations to inhibit binding of [3H]heparin to FGFR4 in solution (Fig. 3A). Whereas low concentrations (1-5 µg/ml) of unlabeled, native heparin blocked the binding almost completely, corresponding amounts of the various selectively desulfated heparin preparations showed little inhibitory capacity. However, each of the preparations resulted in 50-75% inhibition at high concentrations (50-100 µg/ml) (Fig. 3A). In Biacore studies (Fig. 3B), FGFR4 was incubated with the desulfated heparin preparations prior to injection of the mixture over the heparin-coated surface. The results were in agreement with the data from filter trapping assays, such that each of the selective desulfation treatments led to a dramatic decrease in inhibitory capacity (Fig. 3B). Collectively, these results suggest that the N-, 2-O-, and 6-O-sulfate groups of heparin all contribute to binding FGFR4.


View larger version (21K):
[in this window]
[in a new window]
 
Fig. 3.   Binding of selectively desulfated heparin preparations to FGFR4. A, unlabeled, native or selectively N-, 2-O-, or 6-O-desulfated heparin preparations were mixed with [3H]heparin (20 000 dpm) and FGFR4 (15 µg/ml) in PBS. The FGFR4 bound [3H]heparin was quantified by the filter-trapping method. The unlabeled competitors used were native heparin (black-triangle), N-desulfated (black-square), 2-O-desulfated (open circle ), and preferentially 6-O-desulfated () heparin. B, surface plasmon resonance assay of the inhibitory capacity of the selectively desulfated heparin preparations. The native or desulfated saccharides (2.4 µg/ml) were mixed with FGFR4 (1.2 ng/ml) and injected over the heparin-coated surface at a flow of 10 µl/min. The data represent the average of two independent experiments. The sensorgrams pertaining to one of the experiments are shown in the inset (N-DS, N-desulfated heparin; 2-O-DS, 2-O-desulfated heparin; 6-O-DS, 6-O-desulfated heparin; H, native heparin).

Recently, the AT-binding pentasaccharide motif of heparin, containing a critical 3-O-sulfated GlcNSO3 residue was implicated in binding to FGFRs (38). We decided to reassess this proposal by separating 3H-labeled heparin decasaccharides with regard to affinity for AT, and then test the resultant high and low affinity fractions for ability to bind FGFR4. About 2% of the starting material bound with high affinity to immobilized AT, in good agreement with previous findings (29) and this fraction was quantitatively retained by the FGFR4 column (Fig. 4A), in accord with the proposal by McKeehan et al. (38). However, a major portion of the fraction with low affinity for AT also bound to the immobilized FGFR4, and elution of this material from the FGFR4 column required the same NaCl concentration as that needed to displace the decasaccharide with high affinity for AT (Fig. 4A). This finding is in disagreement with the notion that the AT binding sequence is essential for FGFR binding. Indeed, isolation of the two FGFR4-binding fractions followed by analytical AT-Sepharose chromatography confirmed that one of the fractions, as expected, showed high affinity for AT whereas the other did not (Fig. 4B).


View larger version (22K):
[in this window]
[in a new window]
 
Fig. 4.   Binding of antithrombin-fractionated heparin decasaccharides to FGFR4. A, AT binding (---, 20,000 cpm) and nonbinding (- - - -, 24,000 cpm) 3H-labeled heparin decasaccharides were affinity fractionated on the FGFR4 column. Bound decasaccharides were eluted by a linear gradient of NaCl in PBS, as indicated by the dotted line. B, the FGFR4 bound decasaccharides were pooled, desalted, and subjected to chromatography on AT-Sepharose.

Binding of Heparan Sulfate to FGFR4-- The major physiological polysaccharide ligand for FGFR4 is presumably HS rather than heparin, that is essentially confined to the mast cell. The interactions of 3H-labeled HS samples from bovine lung, aorta, and kidney with FGFR4 were studied by affinity chromatography (Fig. 5). All HS species tested were retained by the column and required 0.2-0.3 M NaCl for elution. Generally, the binding was somewhat weaker than that of heparin, judging from the higher NaCl concentration required to displace heparin compared with HS. The FGFR4 binding profiles of the various HS species differed such that a substantial portion of kidney HS emerged at NaCl concentrations >0.35 M, whereas aorta HS contained only minor amounts of such high-affinity material.


View larger version (22K):
[in this window]
[in a new window]
 
Fig. 5.   Binding of heparan sulfate to FGFR4. A, [3H]heparan sulfate (10 000 dpm) from bovine aorta (), kidney (open circle ), and lung () were applied to the column of immobilized FGFR4 in PBS containing 1.3 mM CaCl2. After washing with PBS/CaCl2 the bound material was eluted with a linear gradient of NaCl in the same buffer. Fractions were collected and analyzed for radioactivity and NaCl concentration (- - -).

Disaccharide Composition of FGFR4 Binding Heparan Sulfate Decasaccharides-- We next proceeded to characterize HS domains with affinity toward FGFR4. The experiments with selectively desulfated heparin suggested that the binding of HS to FGFR4 would require highly sulfated structures, of the type represented by the N-sulfated domains of the polysaccharide. These domains are composed of consecutive N-sulfated disaccharide units and contain most of the O-sulfate groups of the HS chain. To isolate such domains, we used bovine intestinal HS that bound to the FGFR4 affinity column (data not shown) similar to the lung HS preparation shown in Fig. 5. N-Sulfated oligosaccharides were prepared as described under "Experimental Procedures" and 3H-end-labeled by reduction with NaB3H4. Affinity chromatography of the [3H]decasaccharide on the FGFR4 column yielded 20% of bound material. After two reapplications of the unbound fraction, less than 4% of the material bound to the matrix, indicating depletion of FGFR4-binding species (data not shown). Analysis of the bound and unbound decamer pools (see "Experimental Procedures") indicated that the bound fraction was markedly enriched in 6-O-sulfate groups, that were almost twice as abundant as in the unbound fraction (Table I, Fig. 6). The 6-O-sulfate groups occurred mainly in trisulfated -IdoA(2-OSO3)-GlcNSO3(6-OSO3)- disaccharide units. Similar results were obtained upon compositional disaccharide analysis of FGFR4 bound and unbound dodecasaccharides (not shown). Together, these findings suggest that the FGFR4-HS interaction is mediated by highly sulfated domains containing both IdoA(2-OSO3) and GlcNSO3(6-OSO3) residues.

                              
View this table:
[in this window]
[in a new window]
 
Table I
Disaccharide composition of FGFR4 unbound and bound heparan sulfate decasaccharides
Decameric N-sulfated domains from bovine intestinal heparan sulfate were fractionated on the FGFR4 affinity column. The unbound and bound pools were cleaved with HNO2, pH 1.5, and the resultant disaccharides were reduced with NaB3H4 and analyzed by anion-exchange chromatography and paper electrophoresis as described under "Experimental Procedures."


View larger version (21K):
[in this window]
[in a new window]
 
Fig. 6.   Compositional disaccharide analysis of FGFR4 binding/nonbinding decasaccharides. N-Sulfated decasaccharides from bovine intestinal HS were fractionated on the FGFR4 affinity matrix. The unbound (A) and bound (B) fractions were recovered and subjected to cleavage by HNO2, pH 1.5, followed by radiolabeling of the resultant disaccharides with NaB3H4. These were separated from unincorporated radioactivity and analyzed by anion exchange HPLC as described under "Experimental Procedures." The peaks correspond to the following disaccharide structures in the native polysaccharide: 1) GlcA(2-OSO3)-GlcNSO3; 2) GlcA-GlcNSO3 (6-OSO3); 3) IdoA-GlcNSO3 (6-OSO3); 4) IdoA(2-OSO3)-GlcNSO3; and 5) IdoA(2-OSO3)-GlcNSO3 (6-OSO3). The asterisk (*) indicates tetrasaccharides, in part due to "anomalous" ring contraction (28), that were not included in the quantification of disaccharides shown in Table I.

Sequence Analysis of FGFR4-binding Heparan Sulfate Domains-- To obtain more detailed information of the FGFR4-binding HS domain, we employed a novel method for sequencing of end-labeled, N-sulfated HS oligosaccharides (33). Affinity chromatography of [3H]octasaccharides (i.e. the smallest fragments containing the FGFR4-binding domain; see Fig. 2) derived from bovine intestinal HS on FGFR4, yielded a fraction (~15% of the starting material) of labeled components that remained bound to the receptor at physiological ionic strength (Fig. 7).


View larger version (17K):
[in this window]
[in a new window]
 
Fig. 7.   FGFR4 affinity fractionation of octasaccharides for sequencing analysis. [3H]Octasaccharides prepared from bovine intestinal HS were fractionated on the FGFR4 affinity column in preparative fashion. Bound octasaccharides were eluted by a stepwise gradient of NaCl (dotted line).

Approximately 60% of the bound octasaccharides were eluted from the FGFR4 affinity column at 0.2 M NaCl (in the following denoted as the 0.2 M fraction) whereas ~30% required 0.3 M NaCl (0.3 M fraction) for displacement (Fig. 7). Further selection of target fractions for sequence analysis within each affinity class aimed for components with the lowest charge density; this approach was adopted to pinpoint the minimal structural features required for FGFR4 binding, without redundant O-sulfate groups. The octasaccharides thus recovered (~10% of the labeled material) from the 0.2 M fraction by preparative Propac PA1 chromatography (not shown) yielded a somewhat heterogeneous peak upon analytical rechromatography (Fig. 8A), at an elution position corresponding to an N-sulfated octasaccharide sequence with three O-sulfate groups.


View larger version (14K):
[in this window]
[in a new window]
 
Fig. 8.   Sequence analysis of minimal FGFR4-binding octasaccharides. The sample is a fraction of HS [3H]octasaccharides, eluted from the FGFR4 column with 0.2 M NaCl. Panels show anion-exchange chromatograms of the material (A) before and (B) after pHNO2 treatment. Samples (6500 dpm) of the pHNO2-treated material were digested with IdoA2Sase (C), IdoA2Sase + IdoAase (D), and IdoA2Sase + IdoAase + GlcN6Sase (E). Di-, tetra-, hexa-, and octasaccharide products obtained after partial HNO2 cleavage are assigned numbers 2 to 8, the attached letter (a and b) identifies the parent octasaccharide sequence. Designations of enzyme digestion products by ', ", and '" indicate removal of 2-OSO3, IdoA, and 6-OSO3, respectively. The peaks in panel B correspond to the following sequences: 8a, GlcA-GlcNSO3-IdoA(2-OSO3)-GlcNSO3(6-OSO3)-IdoA(2-OSO3)-GlcNSO3-GlcA-aManR; 6a, IdoA(2-OSO3)-GlcNSO3(6-OSO3)-IdoA(2-OSO3)-GlcNSO3-GlcA-aManR; 4a, IdoA(2-OSO3)-GlcNSO3-GlcA-aManR; 2a, GlcA-aManR; 8b, GlcA-GlcNSO3-IdoA(2-OSO3)-GlcNSO3-IdoA(2-OSO3)-GlcNSO3-IdoA-aManR(6-OSO3); 6b, IdoA(2-OSO3)-GlcNSO3-IdoA(2-OSO3)-GlcNSO3-IdoA-aManR(6-OSO3); 4b, IdoA(2-OSO3)-GlcNSO3-IdoA-aManR(6-OSO3); and 2b, IdoA-aManR(6-OSO3). For additional information, see text.

Sequence analysis involved pHNO2 treatment followed by Propac chromatography of the resultant, labeled even-numbered oligosaccharide fragments (di-, tetra-, and hexasaccharides from a parental octasaccharide, along with some uncleaved material). These oligosaccharides were then modified further, by stepwise incubations with IdoA2Sase, IdoA2Sase/IdoAase, and IdoA2Sase/IdoAase/GlcN6Sase, the products of each step being analyzed by Propac chromatography (33). Sequence assignment was based on (i) the effects on each oligosaccharide of the various enzyme treatments and (ii) the observed elution positions of the oligosaccharides generated by pHNO2, as related to the behavior of standard oligosaccharides with known numbers of O-sulfate groups.2 The effects on the oligosaccharides of the enzymes were highly reproducible and involved large, predictable shifts in elution position due to removal of sulfate groups, and smaller shifts after removal of nonreducing terminal IdoA residues. Notably, the residual parental oligosaccharides terminate with a GlcA unit (adjacent to a GlcNAc residue in the intact HS chain, hence not subject to C5-epimerization during HS biosynthesis (39)) and therefore resist the enzyme treatment. Even sequences of major components in mixtures could be resolved, based on the identification of distinct equal sized pHNO2 oligosaccharides and the known (identical) number of sulfate groups in the corresponding intact saccharides (tri-O-sulfated octasaccharides in Fig. 8). In cases where deduced structures were not entirely represented by resolved degradation intermediates, the uncertainty in structural assignment has been indicated.

Application of these procedures to the recovered [3H]octasaccharide sample (Propac chromatography) from the 0.2 M fraction (FGFR4 affinity chromatography) yielded the two tri-O-sulfated sequences 8a and 8b shown in Fig. 10. These structures were deduced as follows. A hexasaccharide fraction (6b) appeared following pHNO2 treatment, somewhat retarded compared with the parental octasaccharide fraction (Fig. 8B). This increase in charge density reflected the loss of a non-O-sulfated GlcA-GlcNSO3 disaccharide sequence (units 1 and 2 in Fig. 10; octasaccharides 8a and 8b). The hexasaccharide peak was eliminated by IdoA2Sase digestion, and replaced by two less anionic, incompletely resolved peaks, thus identifying an IdoA(2-OSO3), unit 3. One of these components lost an additional sulfate group by IdoAase/GlcN6Sase treatment, whereas the other remained unaffected (Fig. 8, D and E). Unit 4 thus was 6-O-sulfated in one of the sequences (octasaccharide 8a) but not in the other (octasaccharide 8b). The elution positions of the two major tetrasaccharide products (4a and 4b in Fig. 8B) of pHNO2 treatment suggested a difference in composition by one sulfate group. Both tetrasaccharides were susceptible to Ido2Sase (Fig. 8C) and IdoAase (Fig. 8D), but resistant to GlcN6Sase (Fig. 8E), and therefore both contained a nonreducing-terminal IdoA(2-OSO3)-GlcNSO3-disaccharide sequence (units 5 and 6 in Fig. 10, octasaccharides 8a and 8b). The additional O-sulfate group in octasaccharide 8b was located to the terminal aManR residue by analysis of the labeled disaccharide fractions (2a and 2b in Fig. 8B). None of the disaccharides were affected by IdoA2Sase (Fig. 8C). Fraction 2a, that appeared at the elution position of nonsulfated HexA-aManR, was partially cleaved by IdoAase, yielding nonsulfated labeled monosaccharide; however, the major portion remained unchanged, indicating a -GlcA-aManR- sequence for units 7 and 8 in octasaccharide 8a (Fig. 10). Disaccharide 2b, at the elution position of monosulfated HexA-aManR, was quantitatively converted to labeled aManR(6-OSO3) by digestion with IdoAase (Fig. 8D; the peak coinciding with that of the 4a'" product). This sulfated monosaccharide is not a substrate for GlcN6Sase (Fig. 8E). Octasaccharide 8b thus terminates (units 7 and 8) with an -IdoA-aManR(6-OSO3)- structure (Fig. 10).

An octasaccharide fraction was recovered by preparative Propac chromatography, corresponding to ~10% of the labeled material eluted from the FGFR4 column with 0.3 M NaCl (not shown). Analytical Propac assessment showed a peak at an elution position consistent with the occurrence of N-sulfated octasaccharides containing four O-sulfate groups (Fig. 9A; cf. elution position of analogs with three O-sulfate groups in Fig. 8A). Of the fragments generated upon pHNO2 treatment (Fig. 9B), hexasaccharide 6c, tetrasaccharide 4c, and disaccharide 2c could be assigned to the parent octasaccharide 8c shown in Fig. 10. Briefly, the elution position of 6c reflects the loss of a terminal mono-O-sulfated disaccharide residue, defining units 1-2 as GlcA-GlcNSO3(6-OSO3) (see above). Treatment with IdoA2Sase produced major shifts in the positions of subfractions 6c and 4c, indicating loss of a 2-O-sulfate group from each fragment (Fig. 9C). Digestion with IdoAase led to the predicted, less prominent, shifts for 6c', 4c', and 2c, as expected for nonreducing-terminal IdoA residues (Fig. 9D). The elution position of the intact disaccharide 2c is that of IdoA-aManR(6-OSO3) (Fig. 9B). None of these three components were further affected by digestion with GlcN6Sase (Fig. 9E).


View larger version (14K):
[in this window]
[in a new window]
 
Fig. 9.   Sequence analysis of octasaccharides binding FGFR4 with higher affinity. The sample is a fraction of HS [3H]octasaccharides, eluted from the FGFR4 column with 0.3 M NaCl. The various degradation treatments illustrated in panels B-E are the same as shown in Fig. 8. For each enzyme digestion 10,000 dpm of pHNO2-treated material was used. The peaks in the chromatograms correspond to the following sequences: 8c, GlcA-GlcNSO3(6-OSO3)-IdoA(2-OSO3)-GlcNSO3-IdoA(2-OSO3)-GlcNSO3-IdoA-aManR(6-OSO3); 6c, IdoA(2-OSO3)-GlcNSO3-IdoA(2-OSO3)-GlcNSO3-IdoA-aManR(6-OSO3); 4c, IdoA(2-OSO3)-GlcNSO3-IdoA-aManR(6-OSO3); 2c, IdoA-aManR(6-OSO3); 4d, IdoA(2-OSO3)-GlcNSO3-GlcA-aManR; 2d, GlcA-aManR; 4e, IdoA(2-OSO3)-GlcNSO3(6-OSO3)-IdoA-aManR(6-OSO3); 2e, IdoA-aManR(6-OSO3).


View larger version (37K):
[in this window]
[in a new window]
 
Fig. 10.   FGFR4 binding heparan sulfate octasaccharide sequences. Octasaccharides 8a and 8b were eluted from the FGFR4 column with 0.2 M NaCl, octasaccharides 8c, 8d, and 8e with 0.3 M NaCl. Sequences 8a-c were completely resolved, whereas sequences 8d and 8e were indirectly deduced from the resolved structures of the corresponding tetrasaccharides, and the known overall degree of O-sulfation (4 residues per molecule) of the parent octasaccharides. The locations of the three O-sulfate groups marked with asterisks in structure 8d (units 2-4) are tentative but highly plausible, since tetrasaccharide 4d was shown to contain only one O-sulfate residue (unit 5). Conversely, only one of the three positions occupied by unspecified R residues in sequence 8e carries an O-sulfate group, the remaining three O-sulfate residues being assigned to units 5, 6, and 8. In some of the octasaccharides unit 7 can be either GlcA or IdoA; the sequences shown represent the predominant structures. The hydrogen and hydroxyl groups are not shown.

Additional fragments created by pHNO2 treatment of the tetra-O-sulfated octasaccharide fraction included the two tetrasaccharides 4d and 4e, and the disaccharide 2d. Due to lack of any detectable corresponding hexasaccharide fragments, the sequences of the parental octasaccharides could not be directly resolved. However, fragments 4d and 2d appeared to derive from a common parent structure, since 4d was identified as a mono-O-sulfated tetrasaccharide with nonreducing terminal IdoA(2-OSO3)-saccharide, and 2d as a nonsulfated disaccharide (Fig. 9, B-E). Presumably, the parent octasaccharide 8d contains three additional O-sulfate groups that would be distributed among units 2-4, as shown in Fig. 10. Fragment 4e emerged like a tri-O-sulfated heparin tetrasaccharide (Fig. 9B), and the effects of enzyme digestions indicated a nonreducing-terminal IdoA(2-OSO3)-GlcNSO3(6-OSO3)-disaccharide sequence (Fig. 9, C-E), thus a structure not represented by any of the four identified octasaccharide sequences 8a-d (Fig. 10). Octasaccharide 8e thus would contain one additional O-sulfate group at an undetermined site within units 2-4.

    DISCUSSION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

In this study we have resolved octasaccharide sequences (Fig. 10) with affinity toward FGFR4. The structures represent the first HS sequences shown to bind FGF receptors. To the best of our knowledge, they also represent the first application of the exoenzyme-based sequencing technology (33) to HS oligosaccharides with known protein binding activity.

Both heparin and HS were shown to bind to the extracellular domain of FGFR4 independently of FGF ligands. The binding of heparin was saturable, with a KD of 0.3-0.4 µM, thus close to the affinity proposed for binding of heparin to FGFR2-IIIb (0.2 µM) (40). The FGFR-heparin interactions appear to be considerably weaker than those between FGFs and heparin, suggesting that heparan sulfate in vivo would be more prone to bind free FGFs and FGF·FGFR complexes than free FGFR. The KD values for binding of FGF1 and FGF2 to heparin have been reported to be in the nanomolar range (~100 and ~2 nM, respectively) (41, 42).

The minimal heparin domain binding to FGFR4 is contained within 8 monosaccharide units. However, longer oligosaccharides displayed more efficient binding, possibly reflecting a "ladder effect," i.e. the presence of multiple, overlapping binding sites in the longer oligosaccharides. Heparin deca- and dodecasaccharides, perhaps even octasaccharides, appear sufficient for the induction of FGF2 biological activity in cells expressing FGFR1 (11, 18, 43, 44), but the corresponding requirements for FGFR4-expressing cells have not been established. The molecular organization of the ternary complexes between FGFRs, FGFs, and heparin/HS is still unclear. However, recent analyses of crystallized complexes of FGFs (FGF1 or FGF2) and FGFRs (FGFR1 or FGFR2), with or without heparin oligosaccharides, provide novel clues as to how heparin/HS might participate in FGF signaling (9, 10, 45, 46). While the resultant models differ regarding the precise mode of interaction or even the stoichiometry of components involved, they all agree with previous proposals (11, 12, 18) of saccharides interacting with both the growth factor and the receptor moieties. These findings raise intriquing questions concerning the specificity of the interactions with regard to carbohydrate structure.

Previous studies have shown that the minimal structural requirements for interaction of heparin/HS chains with FGF1 and FGF2 are specific and distinctly different (see "Introduction"). In this study we have evaluated the requirements for FGFR4 binding. Highly stringent structure/function relations were proposed by McKeehan et al. (38), who claimed that a number of FGFR species bind exclusively to the AT-binding sequence of heparin. The present results demonstrate that heparin decasaccharides with high and low affinity for AT can bind equally well to FGFR4 (Fig. 4). The reason for this discrepancy is unclear. Assessment of a FGF2:FGFR1:heparin decamer crystal suggested that the N-, 2-O-, and 6-O-sulfate groups of the saccharide are all involved in binding to the receptor component, the 6-O-sulfate groups appearing to be of importance (9). These findings agree with the present compositional analysis of HS decasaccharides fractionated with regard to affinity for FGFR4, that indicated appreciable enrichment of 6-O-sulfate groups in the bound fraction (Table I), and with previous functional studies pointing to a role for 6-O-sulfate groups in HS-FGFR1 binding (11). Moreover, competitive binding of [3H]heparin and various desulfated unlabeled heparin preparations to FGFR4 clearly implicated all three kinds of sulfate substituents in the interaction (Fig. 3). The question then arises whether binding to FGFR4 requires any specific disposition of these residues. All FGFR4-binding HS octasaccharides defined with regard to sequence (Fig. 10) were fully N-sulfated and showed the same distribution of IdoA(2-OSO3) groups, invariably present in both internal disaccharide units. Whether both of these 2-O-sulfate groups are indeed required for FGFR4 binding or simply occur in most or all of the isolated octasaccharides remains unclear. By contrast, the distribution of GlcN(6-OSO3) residues varied conspicuously. The two octasaccharides (8a and 8b) recovered by elution of the FGFR4 column with 0.2 M NaCl both contained a single 6-O-sulfate group, but in different positions (units 4 and 8, respectively). If indeed 6-O-sulfate groups contribute to the interaction their precise location thus does not appear to be critical. Analysis of the octasaccharide species eluted with 0.3 M NaCl, hence with higher affinity for the receptor, reinforces this impression. In all, three components were considered, each containing a total of four O-sulfate groups. Even if only octasaccharide 8c could be pursued through the complete sequencing protocol, the information regarding octasaccharides 8d and 8e sufficed to demonstrate that the 0.3 M fraction contained octasaccharide species with highly diverse 6-O-sulfation patterns (Fig. 10). Yet these 6-O-sulfate groups clearly contribute to the higher overall ligand affinity of the 0.3 M fraction. We conclude that this increase in affinity is due to charge interactions at various locations of the saccharide:FGFR4 interface. Whether this diversity reflects nonspecific polyelectrolyte effects or selective interactions with distinct basic amino acid residues remains to be determined through more refined analysis at the molecular and atomic levels.

What is the functional significance of interactions between FGFRs and heparin-related GAGs? Notably, highly sulfated polyanions such as heparin and synthetic polysulfonates, but not HS that is less sulfated, can activate FGFR4 in the absence of a FGF ligand (20). This effect of heparin is not well understood, but could conceivably be of importance upon heparin release from degranulating mast cells in tissues with abundant FGFR4 expression. However, the major role in vivo of the "heparin-binding domain" of FGFR4 is presumably to mediate the formation of ternary complexes with HS proteoglycans and FGFs, leading to receptor activation. The interpretation of the present data is hampered by a lack of information regarding the functional and topological organization of HS proteoglycan species in the intact tissue, here intestinal mucosa, used as source of HS for oligosaccharide generation. Thus we do not know whether the HS sequences found to bind FGFR4 were actually designed for such interaction in vivo. The relatively modest affinities observed do not argue against an essential functional role in promoting formation of ternary complex (47). However, for productive interactions the FGFR-binding sequences must be contiguous with (or partially overlap) the FGF-binding domains, hence the need for an overall deca- to dodecamer N-sulfated region of the HS chain to accommodate both binding sites. Such regions account for only a small proportion, usually a few percent, of the total HS chains (48). The structural characteristics required for productive interactions of a particular FGF and its receptor with an N-sulfated HS domain remain unclear. At least some of the members of the FGF family, such as FGF1 and FGF2, show highly distinct requirements for HS ligand structure (26, 49), but these features appear to be complemented by less exacting terms for FGFR binding. N-Sulfated domains that are too short, or otherwise structurally unfit to simultaneously interact with both FGF and its receptor, may store the growth factor in the pericellular environment and actually inhibit receptor activation (50, 51). Heparin, frequently used as a substitute for HS in experimental work, consists largely of trisulfated -IdoA(2-OSO3)-GlcNSO3(6-OSO3)- disaccharide units, and thus will basically cover most or all combinations of N- and O-sulfate groups required for interactions with different FGFs and FGFRs. By contrast, HS oligosaccharides with closely similar composition can be fractionated into species that either activate or inhibit FGF2 signaling in HS-deficient cells (18). Moreover, the preference for growth factor target (FGF1 or FGF2) could be shifted by subtle changes in HS structure (52-54). These findings emphasize the need for further analysis, not only of HS structures in relation to growth factor action, but also of the mechanisms that control the generation of such structures during their biosynthesis.

    ACKNOWLEDGEMENTS

We thank Dr. Jin-Ping Li (Uppsala University) for providing the antithrombin-Sepharose and Dr. Per Jemth (Uppsala University) for help with the affinity calculations.

    FOOTNOTES

* This work was supported by the European Comission programs "Biologically Active Novel Glycosaminoglycans" Grant QLK-CT-1999.00536 and "Heparan Sequencing Demonstration" Grant BIO4-CT98-0538, Swedish Medical Research Council Grants K96-03P and K99-03X, Swedish Cancer Society Grant 3919-B97, Polysackaridforskning AB (Uppsala, Sweden), the Finnish Cancer Union, the Academy of Finland (MATRA-program), and the Juselius Foundation.The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

|| To whom correspondence should be addressed: Turku Centre for Biotechnology, P.O. Box 123, FIN-20521 Turku, Finland. Tel.: 358-2-274-8964; Fax: 358-2-333-8000; E-mail: markku.salmivirta@btk.utu.fi.

Published, JBC Papers in Press, February 21, 2001, DOI 10.1074/jbc.M011226200

2 J. Kreuger and U. Lindahl, unpublished data.

    ABBREVIATIONS

The abbreviations used are: FGF, fibroblast growth factor; AT, antithrombin; aManR, 2,5-anhydromannitol; FGFR, fibroblast growth factor receptor; GlcA, D-glucuronic acid; GlcN, glucosamine; GlcN6Sase, glucosamine 6-sulfatase; GlcNAc, N-acetylglucosamine; GlcNSO3, N-sulfoglucosamine; HexA, hexuronic acid; HPLC, high perfomance liquid chromatography; HSPG, heparan sulfate proteoglycan; IdoA, L-iduronic acid; IdoAase, alpha -L-iduronidase; IdoA2Sase, iduronate 2-sulfatase; SAX, strong anion exchange; HS, heparan sulfate; HSPG, heparan sulfate proteoglycan; PBS, phosphate-buffered saline; MES, 2-N-(morpholino)ethanesulfonic acid.

    REFERENCES
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

1. Burgess, W. H., and Maciag, T. (1989) Annu. Rev. Biochem. 58, 575-606[CrossRef][Medline] [Order article via Infotrieve]
2. Johnson, D. E., and Williams, L. T. (1993) Adv. Cancer Res. 60, 1-41[Medline] [Order article via Infotrieve]
3. Ullrich, A., and Schlessinger, J. (1990) Cell 61, 203-212[Medline] [Order article via Infotrieve]
4. Zimmermann, P., and David, G. (1999) FASEB J. 13, 91-100[Abstract/Free Full Text]
5. Rapraeger, A. C. (1993) Curr. Opin. Cell Biol. 5, 844-853[Medline] [Order article via Infotrieve]
6. Bernfield, M., Kokenyesi, R., Kato, M., Hinkes, M. T., Spring, J., Gallo, R. L., and Lose, E. J. (1992) Annu. Rev. Cell Biol. 8, 365-393[CrossRef]
7. Rapraeger, A. C., Krufka, A., and Olwin, B. B. (1991) Science 252, 1705-1708[Medline] [Order article via Infotrieve]
8. Yayon, A., Klagsbrun, M., Esko, J. D., Leder, P., and Ornitz, D. M. (1991) Cell 64, 841-848[Medline] [Order article via Infotrieve]
9. Schlessinger, J., Plotnikov, A. N., Ibrahimi, O. A., Eliseenkova, A. V., Yeh, B. K., Yaon, A., Linhardt, R. J., and Mohammadi, M. (2000) Mol. Cell 6, 743-750[Medline] [Order article via Infotrieve]
10. Pellegrini, L., Burke, D. F., von Delft, F., Mulloy, B., and Blundell, T. L. (2000) Nature 407, 1029-1034[CrossRef][Medline] [Order article via Infotrieve]
11. Guimond, S., Maccarana, M., Olwin, B. B., Lindahl, U., and Rapraeger, A. C. (1993) J. Biol. Chem. 268, 23906-23914[Abstract/Free Full Text]
12. Kan, M., Wang, F., Xu, J., Crabb, J. W., Hou, J., and McKeehan, W. L. (1993) Science 259, 1918-1921[Medline] [Order article via Infotrieve]
13. Wang, F., Kan, M., Yan, G., Xu, J., and McKeehan, W. L. (1995) J. Biol. Chem. 270, 10231-10235[Abstract/Free Full Text]
14. Kjellén, L., and Lindahl, U. (1991) Annu. Rev. Biochem. 60, 443-475[CrossRef][Medline] [Order article via Infotrieve]
15. Salmivirta, M., Lidholt, K., and Lindahl, U. (1996) FASEB. J. 10, 1270-1279[Abstract/Free Full Text]
16. Rosenberg, R. D., Shworak, N. W., Liu, J., Schwartz, J. J., and Zhang, L. (1997) J. Clin. Invest. 99, 2062-2070[Free Full Text]
17. Rusnati, M., Coltrini, D., Caccia, P., Dell'Era, P., Zoppetti, G., Oreste, P., Valasina, B., and Presta, M. (1994) Biochem. Biophys. Res. Commun. 203, 450-458[CrossRef][Medline] [Order article via Infotrieve]
18. Pye, D. A., Romain, R. V., Turnbull, J. E., Hyde, P., and Gallagher, J. T. (1998) J. Biol. Chem. 273, 22936-22942[Abstract/Free Full Text]
19. Brickman, Y. G., Ford, M. D., Small, D. H., Bartlett, P. F., and Nurcombe, V. (1995) J. Biol. Chem. 270, 24941-24948[Abstract/Free Full Text]
20. Gao, G., and Goldfarb, M. (1995) EMBO J. 14, 2183-2190[Abstract]
21. Loo, B.-M., Darwish, K., Vainikka, S., Saarikettu, J., Vihko, P., Hermonen, J., Goldman, A., Alitalo, K., and Jalkanen, M. (2000) Int. J. Cell Biol. Biochem. 32, 489-497[CrossRef]
22. Lindahl, U., Cifonelli, J. A., Lindahl, B., and Rodén, L. (1965) J. Biol. Chem. 240, 2817-2820[Free Full Text]
23. Höök, M., Riesenfeld, J., and Lindahl, U. (1982) Anal. Biochem. 119, 236-245[Medline] [Order article via Infotrieve]
24. Spillmann, D., Witt, D., and Lindahl, U. (1998) J. Biol. Chem. 273, 15487-15493[Abstract/Free Full Text]
25. Feyzi, E., Lustig, F., Fager, G., Spillmann, D., Lindahl, U., and Salmivirta, M. (1997) J. Biol. Chem. 272, 5518-5524[Abstract/Free Full Text]
26. Kreuger, J., Prydz, K., Petterson, R. F., Lindahl, U., and Salmivirta, M. (1999) Glycobiology 9, 723-729[Abstract/Free Full Text]
27. Maccarana, M., and Lindahl, U. (1993) Glycobiology 3, 271-277[Abstract]
28. Shively, J. E., and Conrad, H. E. (1976) Biochemistry 15, 3932-3942[Medline] [Order article via Infotrieve]
29. Höök, M., Björk, I., Hopwood, J., and Lindahl, U. (1976) FEBS Lett. 66, 90-93[CrossRef][Medline] [Order article via Infotrieve]
30. Kusche, M., Torri, G., Casu, B., and Lindahl, U. (1990) J. Biol. Chem. 265, 7292-7300[Abstract/Free Full Text]
31. Bienkowski, M. J., and Conrad, H. E. (1985) J. Biol. Chem. 260, 356-365[Abstract/Free Full Text]
32. Kusche, M., Lindahl, U., Enerbäck, L., and Rodén, L. (1988) Biochem. J. 253, 885-893[Medline] [Order article via Infotrieve]
33. Vivès, R. R., Pye, D. A., Salmivirta, M., Hopwood, J. J., Lindahl, U., and Gallagher, J. T. (1999) Biochem. J. 339, 767-773[CrossRef][Medline] [Order article via Infotrieve]
34. Turnbull, J. E., Hopwood, J. J., and Gallagher, J. T. (1999) Proc. Natl. Acad. Sci. U. S. A. 96, 2698-2703[Abstract/Free Full Text]
35. Kan, M., Wu, X., Wang, F., and McKeehan, W. L. (1999) J. Biol. Chem. 274, 15947-15952[Abstract/Free Full Text]
36. Kan, M., Wang, F., Kan, M., To, B., Gabriel, J. L., and McKeehan, W. L. (1996) J. Biol. Chem. 271, 26143-26148[Abstract/Free Full Text]
37. Patstone, G., and Maher, P. (1995) J. Biol. Chem. 271, 3343-3346[Abstract/Free Full Text]
38. McKeehan, W. L., Wu, X., and Kan, M. (1999) J. Biol. Chem. 274, 21511-21514[Abstract/Free Full Text]
39. Jacobsson, I., Lindahl, U., Jensen, J. W., Roden, L., Prihar, H., and Feingold, D. S. (1984) J. Biol. Chem. 259, 1056-1063[Abstract/Free Full Text]
40. LaRochelle, W. J., Sakaguchi, K., Atabey, N., Cheon, H.-G., Takagi, Y., Kinaia, T., Day, R. M., Miki, T., Burgess, W. H., and Bottaro, D. P. (1999) Biochemistry 38, 1765-1771[CrossRef][Medline] [Order article via Infotrieve]
41. Mach, H., Volkin, D. B., Burke, C. J., Middaugh, C. R., Linhardt, R. J., Fromm, J. R., Loganathan, D., and Mattsson, L. (1993) Biochemistry 32, 5480-5489[Medline] [Order article via Infotrieve]
42. Lee, M. K., and Lander, A. D. (1991) Proc. Natl. Acad. Sci. U. S. A. 88, 2768-2772[Abstract]
43. Ornitz, D. M., Yayon, A., Flanagan, J. G., Svahn, C. M., Levi, E., and Leder, P. (1992) Mol. Cell. Biol. 12, 240-247[Abstract]
44. Ishihara, M., Tyrrell, D. J., Stauber, G. B., Brown, S., Cousens, L. S., and Stack, R. J. (1993) J. Biol. Chem. 268, 4675-4683[Abstract/Free Full Text]
45. Plotnikov, A. N., Schlessinger, J., Hubbard, S. R., and Mohammadi, M. (1999) Cell 98, 641-50[Medline] [Order article via Infotrieve]
46. Plotnikov, A., Hubbard, S., Schlessinger, J., and Mohammadi, M. (2000) Cell 101, 413-424[Medline] [Order article via Infotrieve]
47. Pantoliano, M. W., Horlick, R. A., Springer, B. A., Van Dyk, D. E., Tobery, T., Wetmore, D. R., Lear, J. D., Nahapetian, A. T., Bradley, J. D., and Sisk, W. P. (1994) Biochemistry 33, 10229-10248[Medline] [Order article via Infotrieve]
48. Safaiyan, F., Lindahl, U., and Salmivirta, M. (2000) Biochemistry 39, 10823-10830[CrossRef][Medline] [Order article via Infotrieve]
49. Ishihara, M. (1994) Glycobiology 4, 817-824[Abstract]
50. Lundin, L., Larsson, H., Kreuger, J., Kanda, S., Lindahl, U., Salmivirta, M., and Claesson-Welsh, L. (2000) J. Biol. Chem. 275, 24653-24660[Abstract/Free Full Text]
51. Ishihara, M., Shaklee, P., Yang, Z., Liang, W., Wei, Z., Stack, R., and Holme, K. (1994) Glycobiology 4, 452-458
52. Nurcombe, V., Ford, M. D., Wildschut, J. A., and Bartlett, P. F. (1993) Science 260, 103-106[Medline] [Order article via Infotrieve]
53. Brickman, Y. G., Ford, M. D., Gallagher, J. T., Nurcombe, V., Bartlett, P. F., and Turnbull, J. E. (1998) J. Biol. Chem. 273, 4350-4359[Abstract/Free Full Text]
54. Nurcombe, V., Smart, C. E., Chipperfield, H., Cool, S. M., Boilly, B., and Hondermarck, H. (2000) J. Biol. Chem. 275, 30009-30018[Abstract/Free Full Text]


Copyright © 2001 by The American Society for Biochemistry and Molecular Biology, Inc.